Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab.

Abstract

PURPOSE:

To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS).

METHODS:

This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen.

RESULTS:

Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months.

CONCLUSIONS:

Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.

• Authors: Maurizio Battaglia Parodi, Pierluigi Iacono, Ilaria Zucchiatti, Francesco Bandello
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 26 Issue 4 Pg. 608-611 ( 2018) ISSN: 1744-5078 [Electronic] England
• PMID: 27892746 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Ranibizumab

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Choroidal Neovascularization (diagnosis, drug therapy, etiology)
• Choroiditis (complications, diagnosis, drug therapy)
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Fundus Oculi
• Humans
• Intravitreal Injections
• Male
• Multifocal Choroiditis
• Prospective Studies
• Ranibizumab (administration & dosage)
• Tomography, Optical Coherence
• Treatment Outcome
• Visual Acuity